Kevin Bitterman

Kevin a partner at Atlas Venture, where he focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Kinaset Therapeutics. Kevin is a co-founder and board member of Disc Medicine, and is chair of the board of Remix Therapeutics and Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. Kevin was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic (NASDAQ:MORF) and Visterra (acquired by Otsuka), and cofounded Genocea Biosciences (NASDAQ: GNCA). He previously served as a director of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Taris Biomedical (acquired by Johnson & Johnson) and Vets First Choice (NASDAQ: CVET) among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin is active in the life science and healthcare start-up community serving as Chair Emeritus of the New England Venture Capital Association (NEVCA) and as a member of the Harvard Medical School Blavatnik Biomedical Accelerator, Blavatnik Therapeutics Challenge Awards and QFASTR Steering Committees. He is also a member of the Isabella Stuart Gardner Museum Board of Advisors. He received a B.A. in biology, summa cum laude, from Rutgers University before completing his Ph.D. in genetics at Harvard Medical School.